GSK Stock Recent News

GSK's NDA for linerixibat, for treating itch in PBC patients, gets FDA review with a decision due in March 2026.

The OECD lowered US GDP forecasts for 2025 and 2026 today. Meta and Constellation are teaming up in a nuclear power supply agreement that will last 20 years.

Glaxo (GSK) reported earnings 30 days ago. What's next for the stock?

Fred Hassan, Carat Group chairman, joins 'Money Movers' to discuss pharma innovation in 2025 and what companies he's watching in the sector.

Here is how GSK (GSK) and Amarin (AMRN) have performed compared to their sector so far this year.

PM, CVS, ET, GSK and NWG, which offer high dividends and carry Zacks buy ranks, are strong picks for stability amid volatile market conditions of 2025.

GSK plc GSK and Spero Therapeutics Inc SPRO on Wednesday announced that the pivotal phase 3 PIVOT-PO trial evaluating tebipenem HBr for complicated urinary tract infections (cUTIs) will stop early for efficacy.

Spero Therapeutics and partner GSK said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the trial early for efficacy.

GSK wins CHMP nod for Blenrep combos in relapsed or refractory multiple myeloma. A decision in the EU is expected in the third quarter of 2025.

GSK's Nucala wins FDA nod for COPD with eosinophilic phenotype, marking its fifth indication and strengthening its respiratory portfolio.